GE Healthcare exploring sale of China unit, source says

GE Healthcare (GEHC.O) is reportedly exploring strategic options for its China unit, including a potential outright sale or stake divestment, with the division valued in the billions of dollars. This consideration follows a 15% revenue decline in the region in 2024, attributed to tariffs, political tensions, and increased domestic competition, reflecting a broader trend of diminishing U.S. corporate optimism in China. The potential divestment highlights the increasing challenges for foreign medical device firms operating within the complex Chinese market.

Analysis

GE Healthcare is undertaking a strategic review of its China operations, with options ranging from a partial stake sale to a complete divestiture of the unit, which is reportedly valued in the billions. This move is a direct response to a challenging operating environment, underscored by a 15% revenue decline from the region in 2024, a drop the company attributes to tariffs. The company's considerations are part of a broader trend of diminishing confidence among U.S. firms in China, as evidenced by an American Chamber of Commerce survey showing business optimism at its lowest level since 1999 due to political tensions, fierce domestic competition, and slowing economic growth. This sentiment is further corroborated by Bristol Myers Squibb's recent decision to sell its stake in a Chinese joint venture. GE Healthcare's CFO has also signaled a strategic shift towards moving production capacity to more 'tariff-friendly geographies,' suggesting this potential divestment is a component of a larger strategy to de-risk its supply chain and mitigate geopolitical headwinds.

Key Decisions for Investors

• Investors should view a potential sale of GE Healthcare's China unit as a move to unlock capital and remove a drag on consolidated revenue, but must monitor the eventual valuation, as a sale under duress could result in a lower-than-expected price.
• The early-stage nature of these discussions introduces uncertainty; therefore, holding a neutral to cautiously optimistic stance on GEHC may be prudent until the financial terms and strategic use of proceeds from any potential transaction are clarified.
• This development, alongside Bristol Myers Squibb's divestiture, serves as a key indicator of accelerating de-risking by U.S. healthcare and technology firms in China, warranting a portfolio review to assess exposure to companies with significant revenue concentration in the region.